Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | CDC25B | P30305 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | APAF1 | O14727 | 2/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5940197 | 0.88 | STAT3 (0.59) | STAT3ALDH1A1ELANEKMT2AMEN1 | |
| SCHEMBL23665465 | 0.87 | NQO1 (0.48) | STAT3ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL25649958 | 0.85 | ALDH1A1 (0.46) | STAT3ALDH1A1ELANEKMT2AMEN1 | |
| SCHEMBL13924975 | 0.85 | ALDH1A1 (0.46) | STAT3ALDH1A1ELANEKMT2AMEN1 | |
| SCHEMBL11928939 | 0.83 | NQO1 (0.48) | STAT3ALDH1A1ELANEKMT2AMEN1 | |
| SCHEMBL28705 | 0.80 | STAT3 (0.56) | STAT3ALDH1A1ELANEKMT2AMEN1 | |
| SCHEMBL7678888 | 0.78 | STAT3 (0.61) | STAT3ALDH1A1ELANEKMT2AMEN1 | |
| SCHEMBL30422 | 0.77 | STAT3 (0.57) | STAT3ALDH1A1ELANEKMT2AMEN1 | |
| SCHEMBL1887185 | 0.77 | STAT3 (0.69) | STAT3ALDH1A1ELANEKMT2AMEN1 | |
| SCHEMBL29365382 | 0.77 | STAT3 (0.69) | STAT3ALDH1A1ELANEKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1134216-B1 | ANTI-DRUG RESISTANT STRAIN AGENTS AND ANTICHLAMYDIA AGENTS | JAPAN SCIENCE & TECH CORP (JP) | 2004-05-06 | — | — | EP | claimed |
| JP-9235280-A | — | — | None | — | — | JP | disclosed |
| JP-9249560-A | — | — | None | — | — | JP | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| US-10851075-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190263768-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL, INC. | 2019-08-29 | — | — | US | disclosed |
| EP-3058941-B1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2019-05-22 | — | — | EP | disclosed |
| US-9834532-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834532-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170197932-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2017-07-13 | — | — | US | disclosed |
| EP-3153508-A1 | NOVEL ANTICANCER AGENT | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2017-04-12 | — | — | EP | disclosed |
| US-8877803-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877803-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20110112180-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112180-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| EP-1134216-B1 | ANTI-DRUG RESISTANT STRAIN AGENTS AND ANTICHLAMYDIA AGENTS | JAPAN SCIENCE & TECH CORP (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-6395773-B1 | BACTERICIDES; FURANONAPHTHOQUINONE COMPOUND | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2002-05-28 | — | — | US | disclosed |
| EP-1134216-A1 | ANTI-DRUG RESISTANT STRAIN AGENTS AND ANTICHLAMYDIA AGENTS | Japan Science and Technology Corporation (JP) | 2001-09-19 | — | — | EP | disclosed |
| JP-H09249560-A | ANTIVIRAL AGENT AND ANTIMICROBIAL AGENT | KAGAKU GIJUTSU SHINKO JIGYODAN | 1997-09-22 | — | — | JP | disclosed |
| JP-H09235280-A | FURANONAPHTHOQUINONE DERIVATIVE AND ANTITUMOR AGENT | KAGAKU GIJUTSU SHINKO JIGYODAN | 1997-09-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112180-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | STAT3, STAT1, STAT5B | STAT3 1/4885ALDH1A1 630/4885ELANE 3233/4885 |
| US-20170197932-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | STAT3, STAT1, JAK2 | STAT3 1/4885ALDH1A1 677/4885ELANE 3415/4885 |
| US-10851075-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | STAT3, STAT1, JAK2 | STAT3 1/4885ALDH1A1 545/4885ELANE 3318/4885 |
| US-20190263768-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | STAT3, STAT1, STAT5B | STAT3 1/4885ALDH1A1 630/4885ELANE 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.